DNX-2401

Phase 2Small molecule

DDNAtrix, Inc.

DNX-2401 is one of 61 small molecule programs targeting Diffuse Intrinsic Pontine Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diffuse Intrinsic Pontine GliomaRecruiting

Pediatric Brain TumorNot yet recruiting

MelanomaNot yet recruiting

Diffuse Intrinsic Pontine GliomaPhase 2

Recruiting

Pediatric Brain TumorPhase 2

Not yet recruiting

MelanomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

191 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

95 2

Opdivo

Mekinist

45 4

Cotellic

Roche

Phase 3

21 5

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 3

39 6

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

35 7

Taxol

Teva

Phase 3

13 8

Mektovi

Pfizer

Phase 3

12 9

Proleukin

IIovance Biotherapeutics, Inc.

Lenvima

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Not yet recruiting

Melanoma

NCT07444606

Q2 2029

Phase 2Not yet recruiting

Pediatric Brain Tumor

NCT07424092

Phase 2Recruiting

Diffuse Intrinsic Pontine Glioma

NCT05009992

Clinical

Trials by Indication[1]

Diffuse Intrinsic Pontine Glioma2 trials

Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas

Completed·—·Phase 1·NCT03178032·12 enrolled

A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT05009992·360 enrolled

Pediatric Brain Tumor1 trial

Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors

Not yet recruiting·—·Phase 2·NCT07424092·39 enrolled

Malignant Glioma1 trial

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

Completed·DDNAtrix, Inc.·Phase 1·NCT00805376·37 enrolled

Pembrolizumab1 trial

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

Completed·DDNAtrix, Inc.·Phase 2·NCT02798406·49 enrolled

Melanoma1 trial

Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07444606·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for DNX-2401. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DNX-2401 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DNX-2401. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — DNAtrix, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDNAtrix, Inc.

DNX-2401

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q2 2029

Trials by Indication[1]

Diffuse Intrinsic Pontine Glioma2 trials

Pediatric Brain Tumor1 trial

Malignant Glioma1 trial

Pembrolizumab1 trial

Melanoma1 trial

References

Drug Info

Quick Facts

Related News